-- Scott Roberts
MONDAY, May 2 (HealthDay News) -- Tradjenta (linagliptin)
tablets, combined with diet and exercise, has been approved by the
U.S. Food and Drug Administration to control blood sugar in people
with type 2 diabetes, the agency said Monday.
People with type 2 diabetes don't produce the pancreatic hormone
insulin, or don't respond to it properly. Insulin helps control the
levels of sugar (glucose) in a person's blood. People with too much
blood sugar at are risk of serious complications including heart
disease, blindness, kidney damage, and nerve damage, the FDA said
in a news release.
Type 2 diabetes is the disease's most common form, affecting up
to 95 percent of the estimated 24 million people with diabetes in
the United States, the FDA said.
Tradjenta boosts hormones that stimulate the release of insulin
after a person eats. The drug was evaluated in clinical trials
involving 3,800 people with type 2 diabetes. The most common
adverse reactions reported included upper respiratory infection,
stuffy nose, sore throat, muscle pain and headache.
Tradjenta should not be used by people with type 1 diabetes or
by those who have above-normal levels of ketones in their blood or
urine, the agency advised.
The drug is co-marketed by Ridgefield, Conn.-based Boehringer
Ingelheim Pharmaceuticals and Indianapolis-based Eli Lilly and
To learn more about type 2 diabetes, visit the
National Diabetes Information Clearinghouse.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.